Literature DB >> 22237727

Pathological and molecular biological approaches to early mesothelioma.

Tohru Tsujimura1, Ikuko Torii, Ayuko Sato, Misa Song, Kazuya Fukuoka, Seiki Hasegawa, Takashi Nakano.   

Abstract

Malignant mesothelioma is an asbestos-related malignancy that arises primarily from mesothelial cells on the serosal surfaces of the pleural, peritoneal, and pericardial cavities. Malignant pleural mesothelioma (MPM) is most common, and its incidence is dramatically increasing worldwide as a result of widespread use of asbestos. Morphological discrimination between MPM and reactive mesothelial hyperplasia is difficult, and the most reliable pathological criterion for malignancy is mesothelial proliferation invading deeply into subpleural adipose tissues. To establish radical cure of MPM, it is crucial to find early-stage MPM of epithelial type, in which mesothelial proliferation is localized on the serosal surface of parietal pleura or limited within the submesothelial fibrous tissues of parietal pleura. The initial clinical presentation for patients with MPM is frequently dyspnea and/or chest pain due to large pleural effusion, and cytological analysis of pleural effusions is valuable to find patients with early-stage MPM of epithelial type. Recently, cytological features of MPM in pleural effusion, molecular markers for MPM, and genetic alternations of MPM have been reported. In this review, we discuss major issues on pathological and molecular biological approaches for diagnosis of early-stage MPM of epithelial type.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22237727     DOI: 10.1007/s10147-011-0369-1

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  62 in total

Review 1.  The cytology of malignant mesothelioma.

Authors:  D Whitaker
Journal:  Cytopathology       Date:  2000-06       Impact factor: 2.073

2.  BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression.

Authors:  D E Jensen; M Proctor; S T Marquis; H P Gardner; S I Ha; L A Chodosh; A M Ishov; N Tommerup; H Vissing; Y Sekido; J Minna; A Borodovsky; D C Schultz; K D Wilkinson; G G Maul; N Barlev; S L Berger; G C Prendergast; F J Rauscher
Journal:  Oncogene       Date:  1998-03-05       Impact factor: 9.867

3.  The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.

Authors:  Matthew Bott; Marie Brevet; Barry S Taylor; Shigeki Shimizu; Tatsuo Ito; Lu Wang; Jenette Creaney; Richard A Lake; Maureen F Zakowski; Boris Reva; Chris Sander; Robert Delsite; Simon Powell; Qin Zhou; Ronglai Shen; Adam Olshen; Valerie Rusch; Marc Ladanyi
Journal:  Nat Genet       Date:  2011-06-05       Impact factor: 38.330

4.  A mouse model recapitulating molecular features of human mesothelioma.

Authors:  Deborah A Altomare; Charles A Vaslet; Kristine L Skele; Assunta De Rienzo; Karthik Devarajan; Suresh C Jhanwar; Andrea I McClatchey; Agnes B Kane; Joseph R Testa
Journal:  Cancer Res       Date:  2005-09-15       Impact factor: 12.701

5.  The use of epithelial membrane antigen and silver-stained nucleolar organizer regions testing in the differential diagnosis of mesothelioma from benign reactive mesothelioses.

Authors:  K D Wolanski; D Whitaker; K B Shilkin; D W Henderson
Journal:  Cancer       Date:  1998-02-01       Impact factor: 6.860

6.  Expression of telomerase reverse transcriptase (TERT) in malignant mesotheliomas.

Authors:  Fumiyuki Kumaki; Toshiaki Kawai; Andrew Churg; Françoise B Galateau-Sallé; Philip Hasleton; Douglas Henderson; Victor Roggli; William D Travis; Philip T Cagle; Victor J Ferrans
Journal:  Am J Surg Pathol       Date:  2002-03       Impact factor: 6.394

7.  Utility of surfactant protein B precursor and thyroid transcription factor 1 in differentiating adenocarcinoma of the lung from malignant mesothelioma.

Authors:  A Khoor; J A Whitsett; M T Stahlman; S J Olson; P T Cagle
Journal:  Hum Pathol       Date:  1999-06       Impact factor: 3.466

8.  Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth.

Authors:  Deborah A Altomare; Huihong You; Guang-Hui Xiao; Maria E Ramos-Nino; Kristine L Skele; Assunta De Rienzo; Suresh C Jhanwar; Brooke T Mossman; Agnes B Kane; Joseph R Testa
Journal:  Oncogene       Date:  2005-09-08       Impact factor: 9.867

9.  Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions.

Authors:  Robert T Pu; Yijun Pang; Claire W Michael
Journal:  Diagn Cytopathol       Date:  2008-01       Impact factor: 1.582

10.  Germline BAP1 mutations predispose to malignant mesothelioma.

Authors:  Joseph R Testa; Mitchell Cheung; Jianming Pei; Jennifer E Below; Yinfei Tan; Eleonora Sementino; Nancy J Cox; A Umran Dogan; Harvey I Pass; Sandra Trusa; Mary Hesdorffer; Masaki Nasu; Amy Powers; Zeyana Rivera; Sabahattin Comertpay; Mika Tanji; Giovanni Gaudino; Haining Yang; Michele Carbone
Journal:  Nat Genet       Date:  2011-08-28       Impact factor: 38.330

View more
  8 in total

1.  Gene expression of mesothelioma in vinylidene chloride-exposed F344/N rats reveal immune dysfunction, tissue damage, and inflammation pathways.

Authors:  Pamela E Blackshear; Arun R Pandiri; Hiroaki Nagai; Sachin Bhusari; Hue-Hua Hong; Thai-Vu T Ton; Natasha P Clayton; Michael Wyde; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2014-06-23       Impact factor: 1.902

2.  Performance of osteopontin in the diagnosis of malignant pleural mesothelioma: a meta-analysis.

Authors:  Hui Lin; Yong-Chun Shen; Hong-Yu Long; Hao Wang; Ze-Yu Luo; Zi-Xuan Wei; Shi-Qi Hu; Fu-Qiang Wen
Journal:  Int J Clin Exp Med       Date:  2014-05-15

3.  Mesothelioma - Update on Diagnostic Strategies.

Authors:  Carmen M Rosario; Xiaoqi Lin; David W Kamp
Journal:  Clin Pulm Med       Date:  2012-11

4.  Spontaneous mesotheliomas in F344/N rats are characterized by dysregulation of cellular growth and immune function pathways.

Authors:  Pamela E Blackshear; Arun R Pandiri; Thai-Vu T Ton; Natasha P Clayton; Keith R Shockley; Shyamal D Peddada; Kevin E Gerrish; Robert C Sills; Mark J Hoenerhoff
Journal:  Toxicol Pathol       Date:  2013-08-26       Impact factor: 1.902

Review 5.  [Surgical aspects of malignant pleural mesothelioma: from the perspective of pathology].

Authors:  A Fisseler-Eckhoff
Journal:  Chirurg       Date:  2013-06       Impact factor: 0.955

6.  Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma.

Authors:  Neetu Kalra; Jingli Zhang; Anish Thomas; Liqiang Xi; Mitchell Cheung; Jacqueline Talarchek; Sandra Burkett; Maria G Tsokos; Yuanbin Chen; Mark Raffeld; Markku Miettinen; Ira Pastan; Joseph R Testa; Raffit Hassan
Journal:  BMC Cancer       Date:  2015-05-08       Impact factor: 4.430

7.  Whole exome and targeted deep sequencing identify genome-wide allelic loss and frequent SETDB1 mutations in malignant pleural mesotheliomas.

Authors:  Hio Chung Kang; Hong Kwan Kim; Sharon Lee; Pedro Mendez; James Wansoo Kim; Gavitt Woodard; Jun-Hee Yoon; Kuang-Yu Jen; Li Tai Fang; Kirk Jones; David M Jablons; Il-Jin Kim
Journal:  Oncotarget       Date:  2016-02-16

Review 8.  Targeting microRNA to improve diagnostic and therapeutic approaches for malignant mesothelioma.

Authors:  Kimberly A Birnie; Cecilia M Prêle; Philip J Thompson; Bahareh Badrian; Steven E Mutsaers
Journal:  Oncotarget       Date:  2017-08-24
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.